An intranasal vacccine for COVID-19 is under development by Indian pharma company Bharat Biotech. It announced yesterday that a unique intranasal vacccine named 'CoroFlu' is under development.
India's drug manufacturers are facing a shortage of raw materials due to suspended supply chains in China. The industry imports about 70 percent of ingredients from its eastern neighbor.
Nearly 70 per cent of the raw material or active pharmaceutical ingredients used by the pharma industry in India is imported from China.